400-859-2883
Your location:Home >News center >Industry News

Industry News

09-152023

ADCs for HER2-Positive, HER2-Negative &am…

Here, we will analyze the three FDA approved ADCs for the HER2-positive, HER2-low, and HER2-negative breast cancers.

ADCs for HER2-Positive, HER2-Negative & HER2-Low Breast Cancers
08-232023

Sales of ADC Drugs From 2020 To 2023

According to the current trend, the total global ADC drug sales are expected to exceed $10 billion in 2023, which will become another important milestone in the ADC field. Below we present th…

Sales of ADC Drugs From 2020 To 2023
08-182023

Summary of Targeted Protein Degradation i…

Summary of targeted protein degradation, such as PROTAC and molecular glues in clinical trials.

Summary of Targeted Protein Degradation in Clinical Trials
08-102023

Overview of New Targets For Anti-tumor Dr…

We will summarize the anti-tumor drug targets that have been newly discovered or have new indications recently.

Overview of New Targets For Anti-tumor Drugs
08-102023

The Role of Helper Lipids in Lipid Nanopa…

What are helper lipids? Whats the role of helper lipids in lipid nanoparticles?

The Role of Helper Lipids in Lipid Nanoparticles
07-282023

ADC Based Combination Therapies: Next Gen…

ADCs are being actively investigated in preclinical and clinical trials in combination with other anticancer agents, including chemotherapy, molecularly targeted agents, and immunotherapy.

ADC Based Combination Therapies: Next Generation ADCs
07-262023

DS-8201 (Enhertu): A Potential ADC Drug T…

Enhertu (fam-Trastuzumab deruxtecan-nxki) is a HER2-targeting ADC drug jointly developed by AstraZeneca and Daiichi Sankyo, also known as DS-8201 or T-DXd.

DS-8201 (Enhertu): A Potential ADC Drug Targeting HER2
07-212023

List of New Anti-cancer Drugs Approved By…

So what are the new anti-cancer drugs approved in the first half of the year? As can be seen from the table below, the new drugs approved by the FDA in the first half of the year covered a v…

List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023
07-142023

Overview of Oral Delivery Strategies for …

We provide an overview of the current landscape of oral peptides in marketing and clinical studies, a review of the forms of delivery used, and a summary and analysis of the common strategies…

Overview of Oral Delivery Strategies for Peptides
06-302023

Combination Therapy of PD-1 Inhibitors An…

If Antibody-drug conjugates (ADC) and PD-1 Inhibitors are used in combination, what kind of sparks will be created?

Combination Therapy of PD-1 Inhibitors And Antibody-drug conjugates (ADC)